Form 4: J&J Executive Broadhurst Reports Share Transactions

Johnson & Johnson's EVP of Global Corporate Affairs, Vanessa Broadhurst, reported multiple transactions involving common stock, including vesting of equity awards and a sale.

Summary

• Vanessa Broadhurst, EVP, Global Corporate Affairs at Johnson & Johnson, reported several transactions involving JNJ common stock and derivative securities.
• Transactions included the vesting of Restricted Share Units (RSUs) and Performance Share Units (PSUs) awarded under the company's Long-Term Incentive Plan.
• On February 13, 2026, 408 shares from RSUs and 8,594 shares from PSUs vested, resulting in an acquisition of 8,902 shares of common stock at $0 cost.
• On February 15, 2026, 492 shares and 526 shares from RSUs vested, resulting in an acquisition of 1,018 shares of common stock at $0 cost.
• Shares were withheld for tax payments upon vesting: 144 shares at $244.55 and 3,748 shares at $244.55 on February 13, 2026; 252 shares at $243.45 and 270 shares at $243.45 on February 15, 2026.
• On February 17, 2026, Broadhurst sold 6,197 shares of common stock at a weighted average price of $243.39.
• New awards included 14,405 Employee Stock Options with an exercise price of $243.45 and 1,034 Restricted Share Units on February 15, 2026.
• Following these transactions, Broadhurst beneficially owned 23,003 shares of common stock directly, along with 491, 1,050, and 1,034 Restricted Share Units, and 14,405 Employee Stock Options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there was a sale of shares, it was accompanied by significant vesting of equity awards and new grants of stock options and RSUs, indicating ongoing executive incentive alignment and compensation realization.

Positives

• Vesting of Restricted Share Units (RSUs) and Performance Share Units (PSUs) indicates successful achievement of performance metrics or tenure requirements.
• Grant of new Employee Stock Options (14,405 units) and Restricted Share Units (1,034 units) on February 15, 2026, aligns executive incentives with long-term company performance.
• The acquisition of common stock through vesting at a $0 cost basis represents a direct increase in the executive's equity holdings without personal capital outlay.

Negatives

• Disposal of 6,197 shares of common stock through a sale transaction on February 17, 2026, at a weighted average price of $243.39, reduces the executive's direct equity stake.
• Significant number of shares (144, 3,748, 252, 270) were withheld for tax payments upon vesting, representing a reduction in the net shares received from equity awards.

Future Outlook

This Form 4 filing primarily details past and current insider transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in this Form 4, are a routine part of executive compensation structures in large pharmaceutical and consumer health companies like Johnson & Johnson. The vesting of equity awards and subsequent tax-related sales or direct sales are common occurrences as executives realize value from their long-term incentive plans. The grant of new options and RSUs indicates a continued commitment to aligning executive interests with shareholder value over the long term, consistent with industry best practices for executive retention and motivation.

Comparison to Industry Standards

• The structure of equity awards, including RSUs, PSUs, and stock options with multi-year vesting schedules, is standard practice across major global corporations, particularly in the healthcare and consumer goods sectors. Companies like Pfizer, Merck, and Procter & Gamble utilize similar long-term incentive plans to retain key executives and incentivize performance.
• The practice of withholding shares for tax obligations upon vesting is a common mechanism for executives to manage their tax liabilities efficiently, observed in filings from peers such as Abbott Laboratories and Bristol-Myers Squibb.
• The sale of shares by an executive, even after vesting, is not uncommon and can be for personal financial planning, diversification, or liquidity, and does not inherently signal a negative outlook on the company, especially when new awards are simultaneously granted.

Stakeholder Impact

• Shareholders: The vesting and granting of equity awards align executive interests with shareholder value, potentially fostering long-term growth. The sale of shares by an executive is a routine event and typically does not indicate a change in company fundamentals.
• Employees: The Long-Term Incentive Plan, under which these awards are granted, is a standard component of executive compensation, reflecting the company's approach to rewarding and retaining key talent.

Next Steps

• Future vesting events for the Restricted Share Units awarded on February 13, 2023, February 15, 2024, February 15, 2025, and February 15, 2026, will occur in annual installments.
• Future vesting events for the Performance Share Units awarded on February 13, 2023, will occur as per their specific performance conditions and vesting schedule.
• Future vesting events for the Employee Stock Options awarded on February 15, 2026, will occur in three equal annual installments beginning on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including the vesting of equity awards, tax-related share withholdings, a personal sale, and new grants of stock options and RSUs. These activities are standard for executives managing their compensation and do not provide new fundamental information about Johnson & Johnson's operational performance or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Trading, Equity Awards, Restricted Share Units, Performance Share Units, Stock Options, Executive Compensation, Vanessa Broadhurst, Share Sale, Vesting